Risk factor
Negligible price volatility
Profitability factor
Greatly overvalued vs peers
About
Fortis Healthcare Limited, an integrated healthcare delivery service provider, offers secondary, tertiary, and quaternary care in India, the United Arab Emirates, Sri Lanka, and internationally. Its healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. The company offers services in the areas of cardiac science, cosmetology, dental science, dermatology, diabetes/endocrinology, emergency medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, haematology, infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, rheumatology, thoracic surgery, transplantation medicine, urology, and other support specialties. As of March 31, 2022, it operated a network of 26 hospitals with approximately 4,300 operational beds. The company also operates approximately 426 diagnostics centers and laboratories; and 2,550 collection centers. The company was incorporated in 1996 and is based in Gurugram, India.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Target Price
The average target price of FORTIS.NS is 990 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati
Buy
Sell